Intensive rituximab regimen in immune‐mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment. (20th November 2020) - Barba, Christophe; Peyre, Marion; Galicier, Lionel; Cathebras, Pascal; Ranta, Dana; Malot, Sandrine; Veyradier, Agnès; Coppo, Paul